Impact of New Biomarkers on Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation
NCT ID: NCT03351816
Last Updated: 2020-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
106 participants
INTERVENTIONAL
2017-12-01
2020-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardioversion group
Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
Cardioversion
External electric shock delivery under general anesthesia.
Ablation group
Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
Ablation of atrial fibrillation
Pulmonary vein isolation by radiofrequency or cryoablation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ablation of atrial fibrillation
Pulmonary vein isolation by radiofrequency or cryoablation.
Cardioversion
External electric shock delivery under general anesthesia.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with persistent atrial fibrillation for whom a decision to perform cardioversion is made.
* Patients with social security coverage, or beneficiary thereof.
* Patients who provide written informed consent.
Exclusion Criteria
* Patients with significant valvular heart disease defined as symptomatic aortic valve disease, severe aortic or mitral stenosis or tricuspid or mitral insufficiency grade 3/4 or 4/4
* Patients with pulmonary arterial hypertension \>45 mmHg on echocardiography
* Patients with chronic respiratory disease, chronic obstructive pulmonary disease stage II, III or IV.
* Patients with a left ventricular ejection fraction \<45%
* Patients with recent (\<1 month) acute decompensation of heart failure
* Patients with recent (\<1 month) acute coronary syndrome
* Anemia (hemoglobin \<10 g/dL)
* Pregnant or lactating women
* Patients with anticipated poor compliance, as assessed by the study investigator
* Patients within the exclusion period of another clinical study
* Patients under legal guardianship
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas Meneveau, MD, PhD
Role: STUDY_DIRECTOR
Centre Hospitalier Universitaire de Besancon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Jean Minjoz
Besançon, , France
CHU François Mitterand
Dijon, , France
CHU Brabois
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Badoz M, Serzian G, Favoulet B, Sellal JM, De Chillou C, Laurent G, Ecarnot F, Bardonnet K, Seronde MF, Schiele F, Meneveau N. MR-proANP, sST2, BNP and sinus rhythm maintenance 1 year after electrical cardioversion for atrial fibrillation. BMC Cardiovasc Disord. 2025 Aug 29;25(1):640. doi: 10.1186/s12872-025-05052-5.
Badoz M, Serzian G, Favoulet B, Sellal JM, De Chillou C, Hammache N, Laurent G, Mebazaa A, Ecarnot F, Bardonnet K, Seronde MF, Schiele F, Meneveau N. Impact of Midregional N-Terminal Pro-Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study. J Am Heart Assoc. 2021 Jul 6;10(13):e020917. doi: 10.1161/JAHA.121.020917. Epub 2021 Jun 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A00731-52
Identifier Type: -
Identifier Source: org_study_id